Brings extensive experience in retinal and ophthalmology diseases MELBOURNE, Australia and PRINCETON, N.J. , April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
April 8, 2024
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair MELBOURNE, Australia and PRINCETON, N.J. , April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage
April 3, 2024
Dr. Julie Clark , SVP Clinical Development ; Dr. Fang Li , SVP Regulatory Affairs, to join February 1st Experienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia , Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT;
February 1, 2024
Opthea to receive remaining US$35m funding under the Development Funding Agreement ( DFA ) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor This financing is non-dilutive to shareholders, with no equity
December 27, 2023